

<b>Statement of Deficiencies</b>	<b>(X1) Provider/Supplier/CLIA Identification Number</b>  51D0233527	<b>(X3) Date Survey Completed</b>  08/26/2024
<b>Name of Provider or Supplier</b>  Wvu Med Princeton Community Hospital Bluefield	<b>Street Address, City, State</b>  500 Cherry St, Bluefield, WV	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

<b>(X4) ID Prefix Tag</b>	<b>Summary Statement of Deficiencies</b>
<b>D0000</b>	<p>An off site, proficiency testing (PT) desk review was conducted for WVU Med Princeton Community Hospital Bluefield Location on August 26, 2024, by the West Virginia Office of Laboratory Services. The laboratory PT evaluations were reviewed for successful participation and compliance with the Federal Clinical Laboratory Improvement Amendments (CLIA) regulations under 42 CFR 493. The identified unsuccessful participation is an initial occurrence and explained below.</p>
<b>D2016</b>	<p><b>SUCCESSFUL PARTICIPATION</b> CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: Based on review of CASPER 155D proficiency testing (PT) report, laboratory evaluations from the College of American Pathologists (CAP), and interview, the</p>

laboratory failed to achieve satisfactory performance for analyte #0505 BUN in the first two consecutive PT events of 2024, resulting in an initial unsuccessful participation. Refer to D2096.

**D2096**

**ROUTINE CHEMISTRY**  
CFR(s): 493.841(f)

Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

Based on review of CASPER 155D proficiency testing (PT) report, laboratory evaluations from the College of American Pathologists (CAP), and interview, the laboratory failed to achieve satisfactory performance for analyte #0505 BUN in the first two consecutive PT events of 2024, resulting in an unsuccessful PT performance. Findings: 1. Review of CASPER 155D report revealed the following unsatisfactory scores for the analyte #0505 BUN: 60% 2024 event 1 60% 2024 event 2 2. Review of CAP laboratory evaluations confirmed the unsatisfactory scores of 60% for the analyte #0505 BUN in each of the two consecutive PT events of 2024. 3. An email exchange with the laboratory director, 8/23/24 at 5:00 PM, confirmed the two consecutive unsatisfactory scores for analyte #0505 BUN and the resulting unsuccessful PT performance.